je.st
news
UPDATE 1-Gilead hepatitis C drug meets goal of 4th late-stage study
2013-02-20 04:29:59| Biotech - Topix.net
Gilead Sciences Inc said its experimental hepatitis C drug sofosbuvir, in a late-stage clinical study, was clearly superior to historical cure rates at both 12 and 16 weeks of treatment in patients who were not helped by prior therapy.
Tags: study
update
goal
drug
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||